Share information
237.00 €
-1.37 %
15/05/2026 17:35
-1.37 %
Open
High
Low
Volume
239.10 €
240.90 €
236.50 €
151,927
Latest News
07-May-2026
UCB, Cancer Research UK and Cancer Research Horizons announce new strategic alliance to accelerate development of novel cancer therapies
03-May-2026
UCB to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers
01-May-2026
UCB announces acquisition of IMIDomics’ Patient Insight Business, strengthening capabilities in immune-mediated inflammatory diseases (IMIDs)
30-Apr-2026
UCB’s General Meeting of Shareholders 2026